Key result
Anti-inflammatory drugs show uncertain clinical benefit for AF prevention despite targeting remodeling.
Why the study?
Atrial fibrillation is a highly prevalent arrhythmia associated with significant morbidity and mortality, with varying prevalence worldwide and unclear associations with structural heart disease.
Anti-inflammatory drugs should not yet enter AF prevention practice; leaves open whether targeted trials can resolve efficacy.
trial fibrillation (AF) is a highly prevalent arrhythmia associated with significant morbidity and mortality because of the hemodynamic impairment and thromboembolic events.AF affects 1-1.5% of the population worldwide; it has been estimated that 2.2 million people in the USA and 4.5 million in Europe have paroxysmal or persistent AF.The estimated prevalence of AF was 0.6% in the Japanese general population in 2005, and it will increase to 1.1% in the 2050s.AF is often associated with structural heart disease; however, a substantial proportion of patients with AF have no detectable structural heart disease.
No takes yet. Share an insight, caveat, or question.
Nobuhisa Hagiwara (2010) conducted an editorial in Atrial Fibrillation. Anti-inflammatory therapies was evaluated. Inflammation contributes to atrial fibrillation via structural and electrical remodeling, but the clinical role of anti-inflammatory drugs for AF prevention remains controversial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: